Previous 10 | Next 10 |
2024-02-20 12:32:42 ET More on Alkermes Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage Alkermes to sell Athlone facility in Ireland to Novo Nordisk for $92.5M Alkermes Q4 2023 Earnings Preview Alkermes plc 2023 Q4 - Results - Earnin...
2024-02-18 05:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-16 11:10:43 ET More on iShares Russell 2000 ETF: IWM: Technical Analysis Says You Should Buy Small Caps IWM: Supply-Side Disinflation Benefits Small Caps The Most Small-Cap ETFs: Performance, Fundamentals, And Rankings For 102 Funds Investors retract ...
2024-02-15 15:08:12 ET Alkermes plc (ALKS) Q4 2023 Earnings Conference Call February 15, 2024, 08:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Tod...
2024-02-15 07:07:23 ET More on Alkermes Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet Alkermes Q4 2023 Earnings Preview Alkermes to sell Athlone facility in Ireland to...
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 PR Newswire — Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Yea...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-02-14 11:25:34 ET More on Alkermes Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet Alkermes to sell Athlone facility in Ireland to Novo Nordisk for $92.5M Seeking A...
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 PR Newswire DUBLIN , Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on ...
2024-02-02 02:15:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc Company Name:
ALKS Stock Symbol:
NASDAQ Market:
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences PR Newswire ̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for ...
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Irela...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...